
|Articles|January 1, 2007
Will prostate cancer respond to metabolic-directed treatment?
Chicago-Findings from systematic research being conducted by researchers at the University of California, Davis suggest that arginine deprivation may be a novel treatment in some prostate cancers.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








